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ABSTRACT
Introduction: Various studies show that moderate elevation of plasma homocysteine level has been associated with 
increased risk for cardiovascular and cerebrovascular disease. Objective: To observe the frequency of increased 
homocysteine level in ischemic stroke patients; and its association with other risk factors. Methodology: Observational 
pilot study was conducted on a sample of 75 ischemic stroke patients, enrolled regardless of their age, gender and 
comorbidities, at Ziauddin university hospital, Karachi. Fasting serum homocysteine, folate and vitamin B12 levels were 
measured. Results were interpreted using spss 20.0. Results and Discussion: Mean homocysteine level in our 
population was 19.51 (SD: 11.47)micromol/l. It was higher in groups with vitamin B12 and folic acid deficiency, 
difference being statistically significant (p=0.013 and 0.017, respectively). Males had greater propensity to 
hyperhomocysteinemia; the mean homocysteine value being higher, and the difference, statistically significant 
(p=0.010). Other factors that affect homocysteine levels were also evaluated, that is hypertension, increased 
cholesterol levels and smoking. There was no significant statistical difference in the homocysteine value between the 
groups of patients who had these risk factors and the groups that did not (p=0.747, 0.252 and 0.565, respectively). 
Conclusion: It was speculated that hyperhomocysteinemia is an imperative risk factor for stroke.
O R I G I N A L  A R T I C L E
INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
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INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
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INTRODUCTION
Frail, Aged; refers to a person over the age of 65 years 
experiencing either chronic illness or disability of any 
form of over 1 year’s duration.[1] Fall is a common 
problem in geriatric population. In our community at 
least 19.3% of older people report history of fall, with a 
higher incidence among people who have associated co 
morbidities like stroke, visual impairments, defective 
foot wear, any type of arthritis & fractures in elderly 
population The risk of falling and as a result of fall being 
injured increase with age because of both physiologic 
and pathologic changes.[2] Frequent falls are a general 
reason for admission of previously independent elderly 
person to long time care institution elderly people 
should take rehabilitation classes for balance and 
appropriate gait to prevent the recurrent falls. This study 
identified the risk factors associated with fall and 
relationship of fall with impaired balance. A biological 
system that enable us to know where our body in the 
environment and to keep a desired position. [3] In 
multiple reviews the strongest risk factor for falls is Gait 
and balance disorders. muscle strength and tone, 
Body-orienting reflexes, and the step length and height 
all diminished with age and decrease the ability to avoid 
a fall after sudden bumped or slip. Though impairment 
in balance is recognized as a major predictor of falls. [4] 
A large proportion of falls in elderly people occurs during 
walking on even level pathways. Moreover, older adults 
are more likely to fall when performing synchronized 
tasks, such as walking while performing other motor or 
cognitive tasks. [5] Fear of fall is an important 
psychosomatic barrier that may need to be carried away 
to improve movement levels in older adults with the 
help of direct supervision of physical therapist in 
activities of daily living. [6] The Activities-specific Balance 
Confidence (ABC) scale was developed to statistically 
calculate the level of confidence in performing different 
specific activities without losing balance and 
confidence. [7] The ABC Scale consists of 16  different 
questions,  in which 0% (no confidence) to 100% 
(complete confidence),.[8] The ‘time get up and go’ test 
(TUG) is a easy, simple to evaluate the lower extremity 
function and mobility and risk fall.[9] The test requires a 
person to stand up from an armchair, walk 3 m (10 Ft.), 
come back to the chair, and sit down. Time taken to 
complete the test is strongly associated to functional 
mobility. [10]
METHODS & METHODOLOGY 
The study design was descriptive cross sectional 
conducted from February 2014 to June 2014 in twin 
cities of Rawalpindi and Islamabad. The sample of 271 
older adults was collected through non-probability 
purposive sampling.  The inclusion criteria were geriatric 
population of either gender in community based and 
people with multiple co morbidities were excluded from 
study. The informed consent was taken from all 
participants. The demographic was noted and a self 
administered questionnaire was designed to collect the 
data of associated factors regarding the previous history 
of fall and issues of balance. The standardized test of 
Activities Based Confidence scale (ABC) was used to 
evaluate the level of confidence during performing 
physical function in daily activities among older adults. 
This is self reported scale and participant reported the 
percentage of confidence in performing physical 
function. The interpretation states that 80%, 50-79% 
and less than 50% score means high, moderate and 
low level of physical functioning respectively. [7] Another 
test Time Up and Go (TUG) was used to measure the 
independence in activities and balance. The score 
reports that the time for TUG <10, <20 and >20 
means freely mobile, mostly independent and impaired 
mobility respectively. [10] The data was analyzed through 
SPSS 21 version and frequency tables and cross 
tabulation for relationship was drawn for results.
RESULTS
The statistical description of this study suggest that out 
of 271 geriatric population from Rawalpindi & 
Islamabad, out of 271 geriatric population 78 
(28.80%) were females & 193 (71.20%) were males. 
(74.2%) people lie in age group of 65-74, (18.5%) 
people lie in age group of 75-84, (5.9%) lie in age 
group of 85-94, (1.5%) lie in age group of 95&above. 
Out of 100%(271), 79.7% history of no fall,(14.4%) 
reported one fall, (5.2%)  twice  fall, (3.7%) three or 
more times fall,  in last 3 months. During time get up 
and go test, (0.7%) were freely mobile, (56.8%) were 
mostly independent, (42.4%) with impaired mobility. 
with high level of physical functioning only 1 was freely 
mobile, 48 were mostly independent and only two had 
impaired mobility. With moderate level of physical 
functioning only 1 was freely mobile, 67 were mostly 
independent and 31 with impaired mobility. With low 
level of physical functioning, no one was freely mobile, 
39 were mostly independent and 82 with impaired 
mobility. The ralationship shows that the older adults 
who have impaire mobility on TUG have 30% (82) and 
11.43% (31) low and moderate level of physical 
functioning on ABC scale respectively. The relationship 
reported that the older adult who were independent on 
TUG have 24.7% (67), 14.39% (39) and 17.7% (48) 
low, moderate and high level of physical functioning on 
ABC scale respectively.
Graph 1: Gender Distribution in sample
Graph 2: Percentage of The Activity-specific balance 
confidence (ABC) scale
Graph 3: Score of timed get up & go test (TUG)
Graph 4: Shows the Relationship between Balance 
confidence and physical functioning 
DISCUSSION 
Falls in older adults and fall risk is reliant on a 
combination of factors (peripheral/central, neurological, 
musculoskeletal, cardio respiratory), which can fluctuate 
significantly from person to person. [11] The most 
important findings of this study revealed that majority of 
older adults have no fall history but still most of them 
have low level of confidence & physical functioning on 
ABC scale. The age group 65-74 showed high score in 
ABC scale with high level of physical functioning. The 
reason may include the majority of age group 65-74. 
The similar research was done by Klima etal. [12]
Another finding of this study include that male older 
adults have high score in ABC scale while women older 
adults have lower it may be the reason of majority but it 
also depends upon the lower physical activity of women 
in older age in Pakistani society. According to Petra Pohl 
etal in their research at baseline 55% women (n = 92) 
and 22% men (n = 14) reported FOF. During the 
follow-up 21% women (n = 35) and 30% men (n = 19) 
experienced recurrent falls.[13]. So this research is in 
the favor of this study which clearly defines that the 
confidence level of older female population is lower 
than males. In this study majority of the moderate level 
of physical functioning have no history of fall which 
eliminate the risk factor of previous fall from the list. 
Majority of the elderly people with impaired mobility 
(TUG >20) have low score & level of physical 
functioning on ABC scale. In this study out of 271 only 
two older adult males have freely mobile (<10sec) 
category of TUG and not a single old female is freely 
mobile in this study. Majority of the female older adults 
lie in the category of impaired mobility (>20sec), and 
majority of the male older adults lie in the category of 
mostly independent (<20sec). According to Daniel 
Schoene  MSc etal Their findings suggest that the TUG 
is not important for selective fallers from non-fallers in 
healthy, high-performance older adults but is of more 
value in less-healthy, lower-performance older people. 
Overall, the analytical ability and analytic accuracy of 
the TUG are at best moderate[14]
CONCLUSION AND RECOMMENDATIONS
The study finally concludes that there is relationship 
between balance confidence and physical functioning. 
The level of confidence directly linked with the 
independent performing of physical functioning. There 
is need to create awareness about balance training to 
prevent from injuries. More research must be 
conducted to explore the others contributing factors.
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  Frequency Percent Valid Cumulative
     Percent Percent
 Normal <14 32 42.7 42.7 42.7
 Moderately Elevated >14 33 44.0 44.0 86.7
Valid
 Severely Elevated >30 10 13.3 13.3 100.0
 Total 75 100.0 100.0
Homocysteine level (�mol/l)
  Homocysteine Folate Vitamin B12
  level   level level (pg/ml)
  (�mol/l)  (ng/ml) 
 Valid 75  75 75
N
 Missing 0  0 0
Mean  19.5152  7.1527 432.5467
Median 16.1500  6.0700 294.0000
Std. Deviation 11.46664 4.50741 293.53122
Minimum 7.02  1.12 150.00
Maximum 50.00  21.50 1000.00
Statistics
INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
          REFERENCES
1.   Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland 
     PM, Shaper AG. Prospective study of serum total 
     homocysteine concentration and risk of stroke in 
      middle-aged British men. Lancet. 1995;346: 1395–1 
      398. 
2.   Graham IM, Daly LE, Refsum HM, Robinson K, 
     Brattstrom LE, Ueland PM, Palma_Reis RJ, Boers 
     GH, Sheahan RG, Israelsson B, Uiterwaal CS, 
     Meleady R, McMaster D, Verhoef P, Witteman JC, 
     de Valk HW, Sales Luis AC, Parrot Rouland FM, Tan 
     KS, Higgins I, Garcon D, Andria G. Plasma 
     homocysteine as a risk factor for vascular disease: 
     the European Concerted Action Project. JAMA. 
     1997;277:1775–1781.
3.   McIlroy SP, Dynan KB, Lawson JT, Patterson CC, 
     Passmore AP. Moderately Elevated Plasma 
     Homocysteine, MethylenetetrahydrofolateReductase 
     Genotype, and Risk for Stroke, Vascular Dementia, 
     and Alzheimer Disease in Northern Ireland. Stroke, 
     2002;33:2351-2356.
4.   Stabler SP, Marcell PD, Podell ER, Allen RH, 
     Savage DG, Lindenbaum J. Elevation of total 
     homocysteine in the serum of patients with 
     cobalamin or folate deficiency detected by capillary 
      gas chromatography-mass spectrometry. J Clin Inv est. 
     1988;81:466–474. 
5.   Nygard O, Vollset SE, Refsum H, Stensvold I, 
     Tverdal A, Nordrehaug JE, Ueland PM, Kvale G. 
      Total plasma homocysteine and cardiovascular risk 
     profile: the HordalandHomocysteine Study. JAMA. 
     1995;274: 1526–1533.
6.   Boushey CJ, Beresford SA, Omenn GS, Motulsky 
     AG. A quantitative assessment of plasma 
      homocysteine as a risk factor for vascular disease: 
     probable benefits of increasing folic acid intakes. 
     JAMA. 1995;274: 1049–1057.
7.   Rolland PH, Friggi A, Barlatier A, et al. 
     Hyperhomocysteinemia-induced vascular damage 
     in the minipig. Captopril-hydrochlorothiazide 
      combination prevents elastic alterations. Circulati on 
     1995; 91:1161.
8.    Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion 
     of vascular smooth muscle cell growth by 
     homocysteine: a link to atherosclerosis. ProcNatl- 
     AcadSci USA 1994; 91:6369.
9.    Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn 
     E. Homocysteine-lowering therapy and stroke risk, 
     severity, and disability: additional findings from 
     HOPE2 trial. Stroke. 2009;40:1365-1372.
10. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, 
     Micks M, McQueen MJ, Probstfield J, Fodor G, 
     Held C, Genest J, Jr. Homocysteine lowering with 
     folic acid and b vitamins in vascular disease. N 
     Engl J Med. 2006;354:1567–1577. 
11. Lonn E, Held C, Arnold JM, Probstfield J, 
     McQueen M, Micks M, Pogue J, Sheridan P, 
     Bosch J, Genest J, Yusuf S. Rationale, design and 
     baseline characteristics of a large, simple, 
     randomized trial of combined folic acid and 
     vitamins b6 and b12 in high-risk patients: The 
     heart outcomes prevention evaluation (HOPE)-2 
     trial. Can J Cardiol. 2006;22:47–53.
12. Toole JF, Malinow MR, Chambless LE, Spence JD, 
     Pettigrew LC, Howard VJ, Sides EG, Wang CH, 
     Stampfer M. Lowering homocysteine in patients 
     with ischemic stroke to prevent recurrent stroke, 
     myocardial infarction, and death: The vitamin 
     intervention for stroke prevention (VISP) randomized 
     controlled trial. JAMA. 2004;291:565–575.
13. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of 
     homocysteine- lowering therapy with folic acid in 
     stroke prevention: a meta-analysis. Stroke. 
     2010;41:1205–1212. 
14. Clarke R, Halsey J, Lewington S, Lonn E, 
     Armitage J, Manson JE, Bonaa KH, Spence JD,
     Nygard O, Jamison R, Gaziano JM, Guarino P, 
     Bennett D, Mir F, Peto R, Collins R. Effects of 
     lowering homocysteine levels with b vitamins on 
     cardiovascular disease, cancer, and cause- 
     specific mortality: meta-analysis of 8 randomized 
     trials involving 37 485 individuals. Arch Intern 
     Med. 2010;170:1622–1631.
15. Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect 
     of homocysteine interventions on the risk of 
     cardiocerebrovascular events: a meta-analysis of 
     randomised controlled trials. Int J ClinPract. 
     2010;64:208–215.
16. Miller ER III, Juraschek S, Pastor-Barriuso R, 
     Bazzano LA, Appel LJ, Guallar E. Meta-analysis of 
     folic acid supplementation trials on risk of 
     cardiovascular disease and risk interaction with 
     baseline homocysteine levels. Am J Cardiol. 
     2010;106:517–527.
17. Saposnik G. The role of vitamin B in stroke 
     prevention: A journey from observational studies 
     to clinical trials and critique of the VITAmins TO 
     Prevent Stroke (VITATOPS). Stroke. 2011;42:8 
     38-842.
INTRODUCTION
Frail, Aged; refers to a person over the age of 65 years 
experiencing either chronic illness or disability of any 
form of over 1 year’s duration.[1] Fall is a common 
problem in geriatric population. In our community at 
least 19.3% of older people report history of fall, with a 
higher incidence among people who have associated co 
morbidities like stroke, visual impairments, defective 
foot wear, any type of arthritis & fractures in elderly 
population The risk of falling and as a result of fall being 
injured increase with age because of both physiologic 
and pathologic changes.[2] Frequent falls are a general 
reason for admission of previously independent elderly 
person to long time care institution elderly people 
should take rehabilitation classes for balance and 
appropriate gait to prevent the recurrent falls. This study 
identified the risk factors associated with fall and 
relationship of fall with impaired balance. A biological 
system that enable us to know where our body in the 
environment and to keep a desired position. [3] In 
multiple reviews the strongest risk factor for falls is Gait 
and balance disorders. muscle strength and tone, 
Body-orienting reflexes, and the step length and height 
all diminished with age and decrease the ability to avoid 
a fall after sudden bumped or slip. Though impairment 
in balance is recognized as a major predictor of falls. [4] 
A large proportion of falls in elderly people occurs during 
walking on even level pathways. Moreover, older adults 
are more likely to fall when performing synchronized 
tasks, such as walking while performing other motor or 
cognitive tasks. [5] Fear of fall is an important 
psychosomatic barrier that may need to be carried away 
to improve movement levels in older adults with the 
help of direct supervision of physical therapist in 
activities of daily living. [6] The Activities-specific Balance 
Confidence (ABC) scale was developed to statistically 
calculate the level of confidence in performing different 
specific activities without losing balance and 
confidence. [7] The ABC Scale consists of 16  different 
questions,  in which 0% (no confidence) to 100% 
(complete confidence),.[8] The ‘time get up and go’ test 
(TUG) is a easy, simple to evaluate the lower extremity 
function and mobility and risk fall.[9] The test requires a 
person to stand up from an armchair, walk 3 m (10 Ft.), 
come back to the chair, and sit down. Time taken to 
complete the test is strongly associated to functional 
mobility. [10]
METHODS & METHODOLOGY 
The study design was descriptive cross sectional 
conducted from February 2014 to June 2014 in twin 
cities of Rawalpindi and Islamabad. The sample of 271 
older adults was collected through non-probability 
purposive sampling.  The inclusion criteria were geriatric 
population of either gender in community based and 
people with multiple co morbidities were excluded from 
study. The informed consent was taken from all 
participants. The demographic was noted and a self 
administered questionnaire was designed to collect the 
data of associated factors regarding the previous history 
of fall and issues of balance. The standardized test of 
Activities Based Confidence scale (ABC) was used to 
evaluate the level of confidence during performing 
physical function in daily activities among older adults. 
This is self reported scale and participant reported the 
percentage of confidence in performing physical 
function. The interpretation states that 80%, 50-79% 
and less than 50% score means high, moderate and 
low level of physical functioning respectively. [7] Another 
test Time Up and Go (TUG) was used to measure the 
independence in activities and balance. The score 
reports that the time for TUG <10, <20 and >20 
means freely mobile, mostly independent and impaired 
mobility respectively. [10] The data was analyzed through 
SPSS 21 version and frequency tables and cross 
tabulation for relationship was drawn for results.
RESULTS
The statistical description of this study suggest that out 
of 271 geriatric population from Rawalpindi & 
Islamabad, out of 271 geriatric population 78 
(28.80%) were females & 193 (71.20%) were males. 
(74.2%) people lie in age group of 65-74, (18.5%) 
people lie in age group of 75-84, (5.9%) lie in age 
group of 85-94, (1.5%) lie in age group of 95&above. 
Out of 100%(271), 79.7% history of no fall,(14.4%) 
reported one fall, (5.2%)  twice  fall, (3.7%) three or 
more times fall,  in last 3 months. During time get up 
and go test, (0.7%) were freely mobile, (56.8%) were 
mostly independent, (42.4%) with impaired mobility. 
with high level of physical functioning only 1 was freely 
mobile, 48 were mostly independent and only two had 
impaired mobility. With moderate level of physical 
functioning only 1 was freely mobile, 67 were mostly 
independent and 31 with impaired mobility. With low 
level of physical functioning, no one was freely mobile, 
39 were mostly independent and 82 with impaired 
mobility. The ralationship shows that the older adults 
who have impaire mobility on TUG have 30% (82) and 
11.43% (31) low and moderate level of physical 
functioning on ABC scale respectively. The relationship 
reported that the older adult who were independent on 
TUG have 24.7% (67), 14.39% (39) and 17.7% (48) 
low, moderate and high level of physical functioning on 
ABC scale respectively.
Graph 1: Gender Distribution in sample
Graph 2: Percentage of The Activity-specific balance 
confidence (ABC) scale
Graph 3: Score of timed get up & go test (TUG)
Graph 4: Shows the Relationship between Balance 
confidence and physical functioning 
DISCUSSION 
Falls in older adults and fall risk is reliant on a 
combination of factors (peripheral/central, neurological, 
musculoskeletal, cardio respiratory), which can fluctuate 
significantly from person to person. [11] The most 
important findings of this study revealed that majority of 
older adults have no fall history but still most of them 
have low level of confidence & physical functioning on 
ABC scale. The age group 65-74 showed high score in 
ABC scale with high level of physical functioning. The 
reason may include the majority of age group 65-74. 
The similar research was done by Klima etal. [12]
Another finding of this study include that male older 
adults have high score in ABC scale while women older 
adults have lower it may be the reason of majority but it 
also depends upon the lower physical activity of women 
in older age in Pakistani society. According to Petra Pohl 
etal in their research at baseline 55% women (n = 92) 
and 22% men (n = 14) reported FOF. During the 
follow-up 21% women (n = 35) and 30% men (n = 19) 
experienced recurrent falls.[13]. So this research is in 
the favor of this study which clearly defines that the 
confidence level of older female population is lower 
than males. In this study majority of the moderate level 
of physical functioning have no history of fall which 
eliminate the risk factor of previous fall from the list. 
Majority of the elderly people with impaired mobility 
(TUG >20) have low score & level of physical 
functioning on ABC scale. In this study out of 271 only 
two older adult males have freely mobile (<10sec) 
category of TUG and not a single old female is freely 
mobile in this study. Majority of the female older adults 
lie in the category of impaired mobility (>20sec), and 
majority of the male older adults lie in the category of 
mostly independent (<20sec). According to Daniel 
Schoene  MSc etal Their findings suggest that the TUG 
is not important for selective fallers from non-fallers in 
healthy, high-performance older adults but is of more 
value in less-healthy, lower-performance older people. 
Overall, the analytical ability and analytic accuracy of 
the TUG are at best moderate[14]
CONCLUSION AND RECOMMENDATIONS
The study finally concludes that there is relationship 
between balance confidence and physical functioning. 
The level of confidence directly linked with the 
independent performing of physical functioning. There 
is need to create awareness about balance training to 
prevent from injuries. More research must be 
conducted to explore the others contributing factors.
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Table 3
Variables Subgroups Frequency Mean Standard p- value
   Homocysteine Deviation
   level  
Age groups Age less than 60 34 21.26 +/-13.55 0.250
 Age more than and  41 18.07 +/-9.32
 equal to 60    
Gender Male 41 22.44 +/-13.38 0.010
 Female 34 15.98 +/-7.37 
Folic acid Deﬁciency 15 27.49 +/-13.83 0.017
 Normal level 60 17.52 +/-9.97 
Vitamin B12 Deﬁciency 15 28.41 +/-14.80 0.013
 Normal level 60 17.29 +/-9.37 
Hypertension Present 70 19.40 +/-11.52 0.747
 Absent 5 21.13 +/-11.87 
Increased Present 20 16.99 +/-11.99 0.252
Cholesterol
 Absent 55 20.44 +/-11.24 
Smoking Smoker 14 17.91 +/-13.60 0.565
 Non-smoker 61 19.88 +/-11.02
INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
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INTRODUCTION
Frail, Aged; refers to a person over the age of 65 years 
experiencing either chronic illness or disability of any 
form of over 1 year’s duration.[1] Fall is a common 
problem in geriatric population. In our community at 
least 19.3% of older people report history of fall, with a 
higher incidence among people who have associated co 
morbidities like stroke, visual impairments, defective 
foot wear, any type of arthritis & fractures in elderly 
population The risk of falling and as a result of fall being 
injured increase with age because of both physiologic 
and pathologic changes.[2] Frequent falls are a general 
reason for admission of previously independent elderly 
person to long time care institution elderly people 
should take rehabilitation classes for balance and 
appropriate gait to prevent the recurrent falls. This study 
identified the risk factors associated with fall and 
relationship of fall with impaired balance. A biological 
system that enable us to know where our body in the 
environment and to keep a desired position. [3] In 
multiple reviews the strongest risk factor for falls is Gait 
and balance disorders. muscle strength and tone, 
Body-orienting reflexes, and the step length and height 
all diminished with age and decrease the ability to avoid 
a fall after sudden bumped or slip. Though impairment 
in balance is recognized as a major predictor of falls. [4] 
A large proportion of falls in elderly people occurs during 
walking on even level pathways. Moreover, older adults 
are more likely to fall when performing synchronized 
tasks, such as walking while performing other motor or 
cognitive tasks. [5] Fear of fall is an important 
psychosomatic barrier that may need to be carried away 
to improve movement levels in older adults with the 
help of direct supervision of physical therapist in 
activities of daily living. [6] The Activities-specific Balance 
Confidence (ABC) scale was developed to statistically 
calculate the level of confidence in performing different 
specific activities without losing balance and 
confidence. [7] The ABC Scale consists of 16  different 
questions,  in which 0% (no confidence) to 100% 
(complete confidence),.[8] The ‘time get up and go’ test 
(TUG) is a easy, simple to evaluate the lower extremity 
function and mobility and risk fall.[9] The test requires a 
person to stand up from an armchair, walk 3 m (10 Ft.), 
come back to the chair, and sit down. Time taken to 
complete the test is strongly associated to functional 
mobility. [10]
METHODS & METHODOLOGY 
The study design was descriptive cross sectional 
conducted from February 2014 to June 2014 in twin 
cities of Rawalpindi and Islamabad. The sample of 271 
older adults was collected through non-probability 
purposive sampling.  The inclusion criteria were geriatric 
population of either gender in community based and 
people with multiple co morbidities were excluded from 
study. The informed consent was taken from all 
participants. The demographic was noted and a self 
administered questionnaire was designed to collect the 
data of associated factors regarding the previous history 
of fall and issues of balance. The standardized test of 
Activities Based Confidence scale (ABC) was used to 
evaluate the level of confidence during performing 
physical function in daily activities among older adults. 
This is self reported scale and participant reported the 
percentage of confidence in performing physical 
function. The interpretation states that 80%, 50-79% 
and less than 50% score means high, moderate and 
low level of physical functioning respectively. [7] Another 
test Time Up and Go (TUG) was used to measure the 
independence in activities and balance. The score 
reports that the time for TUG <10, <20 and >20 
means freely mobile, mostly independent and impaired 
mobility respectively. [10] The data was analyzed through 
SPSS 21 version and frequency tables and cross 
tabulation for relationship was drawn for results.
RESULTS
The statistical description of this study suggest that out 
of 271 geriatric population from Rawalpindi & 
Islamabad, out of 271 geriatric population 78 
(28.80%) were females & 193 (71.20%) were males. 
(74.2%) people lie in age group of 65-74, (18.5%) 
people lie in age group of 75-84, (5.9%) lie in age 
group of 85-94, (1.5%) lie in age group of 95&above. 
Out of 100%(271), 79.7% history of no fall,(14.4%) 
reported one fall, (5.2%)  twice  fall, (3.7%) three or 
more times fall,  in last 3 months. During time get up 
and go test, (0.7%) were freely mobile, (56.8%) were 
mostly independent, (42.4%) with impaired mobility. 
with high level of physical functioning only 1 was freely 
mobile, 48 were mostly independent and only two had 
impaired mobility. With moderate level of physical 
functioning only 1 was freely mobile, 67 were mostly 
independent and 31 with impaired mobility. With low 
level of physical functioning, no one was freely mobile, 
39 were mostly independent and 82 with impaired 
mobility. The ralationship shows that the older adults 
who have impaire mobility on TUG have 30% (82) and 
11.43% (31) low and moderate level of physical 
functioning on ABC scale respectively. The relationship 
reported that the older adult who were independent on 
TUG have 24.7% (67), 14.39% (39) and 17.7% (48) 
low, moderate and high level of physical functioning on 
ABC scale respectively.
Graph 1: Gender Distribution in sample
Graph 2: Percentage of The Activity-specific balance 
confidence (ABC) scale
Graph 3: Score of timed get up & go test (TUG)
Graph 4: Shows the Relationship between Balance 
confidence and physical functioning 
DISCUSSION 
Falls in older adults and fall risk is reliant on a 
combination of factors (peripheral/central, neurological, 
musculoskeletal, cardio respiratory), which can fluctuate 
significantly from person to person. [11] The most 
important findings of this study revealed that majority of 
older adults have no fall history but still most of them 
have low level of confidence & physical functioning on 
ABC scale. The age group 65-74 showed high score in 
ABC scale with high level of physical functioning. The 
reason may include the majority of age group 65-74. 
The similar research was done by Klima etal. [12]
Another finding of this study include that male older 
adults have high score in ABC scale while women older 
adults have lower it may be the reason of majority but it 
also depends upon the lower physical activity of women 
in older age in Pakistani society. According to Petra Pohl 
etal in their research at baseline 55% women (n = 92) 
and 22% men (n = 14) reported FOF. During the 
follow-up 21% women (n = 35) and 30% men (n = 19) 
experienced recurrent falls.[13]. So this research is in 
the favor of this study which clearly defines that the 
confidence level of older female population is lower 
than males. In this study majority of the moderate level 
of physical functioning have no history of fall which 
eliminate the risk factor of previous fall from the list. 
Majority of the elderly people with impaired mobility 
(TUG >20) have low score & level of physical 
functioning on ABC scale. In this study out of 271 only 
two older adult males have freely mobile (<10sec) 
category of TUG and not a single old female is freely 
mobile in this study. Majority of the female older adults 
lie in the category of impaired mobility (>20sec), and 
majority of the male older adults lie in the category of 
mostly independent (<20sec). According to Daniel 
Schoene  MSc etal Their findings suggest that the TUG 
is not important for selective fallers from non-fallers in 
healthy, high-performance older adults but is of more 
value in less-healthy, lower-performance older people. 
Overall, the analytical ability and analytic accuracy of 
the TUG are at best moderate[14]
CONCLUSION AND RECOMMENDATIONS
The study finally concludes that there is relationship 
between balance confidence and physical functioning. 
The level of confidence directly linked with the 
independent performing of physical functioning. There 
is need to create awareness about balance training to 
prevent from injuries. More research must be 
conducted to explore the others contributing factors.
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